661 abstracts found.



Results filter

Computational Pathology: Challenges and Opportunities

Year:

Session type:

Nasir Rajpoot1
1University of Warwick

DNA damage repair inhibitors and radiation- are normal tissues spared?

Year:

Session type:

Susan Short1
1University of Leeds

High-dose chemotherapy (HDCT) in relapsed or refractory metastatic germ cell cancer: the Scotland experience.

Year:

Session type:

Yun Yi Tan1,Bahaa Al-Bubseeree1,David Irvine2,Graham MacDonald3,Grant McQuaker2,Anne Parker2,Ashita Waterston1,Jeff White1
1Beatson West of Scotland Cancer Centre,2Queen Elizabeth University Hospital, NHS GGC,3Aberdeen Royal Infirmary, NHS Grampian

NGS analysis of subsequent second primary malignant neoplasms in long-term pancreatic cancer survivors

Year:

Session type:

Tomas Zemanek1,Marketa Janatova2,Martin Lovecek3,Pavel Skalicky3,Roman Havlik3,Jiri Ehrmann4,Ondrej Strouhal1,Petra Zemankova2,Klara Lhotova2,Marianna Borecka2,Jana Soukupova2,Hana Svebisova1,Pavel Soucek5,Viktor Hlavac5,Zdenek Kleibl2,Cestmir Neoral3,Bohuslav Melichar1,Beatrice Mohelnikova-Duchonova1
1Department of Oncology and Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic,2Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic,3Department of Surgery I, Faculty of Medicine and Dentistry, Palacky University Olomouc, University Hospital Olomouc, Czech Republic,4Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, University Hospital Olomouc, Czech Republic,5Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Czech Republic

The use of selenium and vitamin E supplementation to prevent recurrence of non-muscle-invasive bladder cancer: results of the SELENIB trial

Year:

Session type:

Richard Bryan1,Sarah Pirrie1,Ben Abbotts1,Vinnie During1,Carolyn Langford1,Margaret Grant1,Deborah Bird1,Adam Devall1,Gareth Bicknell1,D Michael A Wallace1,Nicholas James1,Lucinda Billingham1,Maurice Zeegers2,Kar Keung Cheng1
1University of Birmingham,2University of Birmingham & University of Maastricht

OPTIMA, a prospective randomised trial to validate the clinical and economic utility of tumour gene expression test use for prediction of chemotherapy sensitivity in high-risk early breast cancer

Year:

Session type:

Rob Stein1,Andreas Makris2,Luke Hughes-Davies3,Iain Macpherson4,Andrea Marshall5,Georgina Dotchin5,Peter Hall6,David Cameron6,Bjørn Naume7,Helena Earl8,Stuart McIntosh9,Sarah Pinder10,Jeremy Thomas6,Christopher Poole11,Daniel Rea12,John Bartlett13,Adrienne Morgan14,Leila Rooshenas15,Carmel Conefrey15,Jenny Donovan15,Claire Hulme16,Victoria Harmer17,Helen Higgins5,Janet Dunn5
1UCL,2Mount Vernon Cancer Centre, East and North Hertfordshoire NHS Trust,3Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust,4University of Glasgow,5University of Warwick,6University of Edinburgh,7Oslo University Hospital,8Cambridge University Hospitals,9Queen's University, Belfast,10King's College London,11University Hospitals Coventry and Warwickshire NHS Trust,12University of Birmingham,13Ontario Institute for Cancer Research MaRS Centre,14ICPV,15University of Bristol,16University of Leeds,17Imperial College Healthcare NHS Trust

The interaction of galectin-3 with TAM receptors in activating signalling pathways for human cancer cell survival and migration.

Year:

Session type:

Nour Al Kafri1,Sassan Hafizi1
1University of Portsmouth

Real-world experience with sorafenib for advanced Hepatocellular Carcinoma (HCC) in a Scottish Population

Year:

Session type:

Adam Peters1
1NHS GGC

Self-management self-efficacy in people living with and beyond cancer (PLWABC) post-treatment: A rural-urban comparison in the East Midlands of England.

Year:

Session type:

David Nelson1,Ros Kane1,Ian McGonagle1,Paul Turner1,Christine Jackson1,Gianina Postavaru2
1University of Lincoln,2Bishop Grosseteste University

Alternative Fixative for Genome Friendly Tissue Handling to Implement Genomic Analysis in the 100,000 Genomes Project

Year:

Session type:

Clare Craig1,Emily Shaw2,Rachel Nelan3,Sally Smith4,Noor Jahan4,Victoria Hipperson4,Faisal Mihaimeed4,Shirley Henderson1,Miao He5,Zoya Kingsbury5,Lisa Browning6,Margaret Ashton-Key7,Afshan Siddiq1,Emma Walsh1,Kay Lawson1,Martina Mijiskovic1,Alona Sosinsky1,Greg Elgar1,Joanne Mason1,Tom Fowler1,James Brenton8,Mark Ross5,Louise Jones9
1Genomics England,2University Hospital Southampton NHS Trust,3Queen Mary University,4Barts Health NHS Trust,5Illumina,6Oxford Health NHS Foundation Trust,7Southampton University Hospital NHS Trust,8Cancer Research UK's Cambridge Institute,9Genomics England; Queen Mary University London and Barts Health NHS Trust

Utilisation of PET-CT Following Chemoradiation for Locally Advanced Head and Neck Cancer.

Year:

Session type:

Mark Winton1,Joanna Mackenzie1,Devraj Srinivasan1,Martin Doak1
1NHS Lothian

One Year Results from a South Wales Rapid Diagnostic Clinic for Patients with Serious but Non-Specific Symptoms of Cancer

Year:

Session type:

Kieran Foley1,Balan Palaniappan2,Anthony Gibson2,Gareth Davies2
1Cardiff University,2Cwm Taf University Health Board

How well are we as Physicians Managing EGFR Inhibitor-induced Cutaneous Toxicity?

Year:

Session type:

Lorna Dodd1,Jenny Smith2
1Newcastle Cancer centre,2Newcastle Cancer Centre

Longitudinal association of plasma cytokines with survival in advanced gastro-oesophageal adenocarcinoma

Year:

Session type:

Alan Bilsland1,Sofie Degerman2,Mattius Landfors2,Jennifer Walker3,Carol McCormick3,Eilidh McCulloch4,Liz-Anne Lewsley5,Antonia MacMillan5,Martin MacLeod3,Jamie Stobo5,Goran Roos2,James Paul5,Jeff Evans4,Fiona Thomson4,W.nicol Keith6
1Institute of Cancer Science, Wolfson Wohl Cancer Research Centre, University of Glasgow,2Umea University,3Glasgow ECMC, Institue of Cancer Science, University of Glasgow,4Glasgow ECMC, Institute of Cancer Science, University of Glasgow,5CRUK Clinical Trials Unit, Institute of Cancer Science, University of Glasgow,6Institute of Cancer Science, University of Glasgow

Exploring distribution of the adult cancer nursing workforce in England

Year:

Session type:

Georgina Smerald1,Rachel White1,Jacqueline Goodchild1
1Macmillan Cancer Support

Phenotypic changes induced by low concentration of glutamine in pancreatic cancer cells: Effects of a hypomethylating therapy

Year:

Session type:

Jose Neptuno Rodriguez-Lopez1,Maria Fernanda Montenegro1,Luis Sanchez-del-Campo1,Rebeca Gonzalez-Guerrero1,Juan Cabezas-Herrera2
1University of Murcia,2Instituto Murciano de Investigación Biosanitaria. University Hospital Virgen de la Arrixaca

Genomic investigation of low grade serous ovarian cancer reveals unique therapeutic vulnerabilities

Year:

Session type:

Dane Cheasley1,Anna deFazio2,Abhimanyu Nigam1,Martin Kobel3,Kylie Gorringe1,Ian G Campbell1
1Peter MacCallum Cancer Centre,2Australian Ovarian Cancer Study,3University of Calgary

ROR1- A biomarker for chemoresistance in ovarian cancer.

Year:

Session type:

Eamaan Syed1,Frank Hills1,Britta Stordal1
1Middlesex University

The social impact of prostate cancer: Findings from the Life After Prostate Cancer Diagnosis (LAPCD) study.

Year:

Session type:

Penny Wright1,Sarah Wilding1,Amy Downing1,Peter John Selby1,Luke Hounsome2,Eila Watson3,Richard Wagland4,Hugh Butcher1,Paul Kind1,Dyfed Huws5,Therese Kearney6,Rebecca Mottram1,Majorie Allen1,Adam Glaser1,Anna Gavin6
1University of Leeds,2Public Health England,3Oxford Brookes University,4University of Southampton,5Welsh Cancer Intelligence & Surveillance Unit,6Queen's University Belfast

TBX2 interacts with Heterochromatin Protein 1 to recruit a novel repression complex to EGR1-responsive promoters and promote the proliferation of breast cancer cells

Year:

Session type:

Alexander McIntyre1,Nyree Crawford1,Anna McCormick1,Zenobia D'Costa1,Naomi Dickson1,Niamh Buckley1,Paul Mullan1
1QUB

The impact of cardiovascular co-morbidities on surgical resection rate in patients with Non-Small Cell Lung Cancer: an analysis of the VICORI cardio-oncology programme

Year:

Session type:

Catherine Welch1,Michael Sweeting1,Mark Rutherford1,Paul Lambert1,Ruth Jack2,David Adlam1,Michael Peake2
1University of Leicester,2Public Health England

Clinical trial methodology in evaluating the benefits of proton beam therapy: a systematic review

Year:

Session type:

Mercy Ofuya1,Lucy McParland2,Sarah Brown2,Louise Murray2,David Sebag-Montefiore2,Emma Hall1
1Institute of Cancer Research,2University of Leeds

Systemic Anti-Cancer Therapy (SACT) in elderly patients with urological malignancy

Year:

Session type:

Dorothy Yang1,Victoria Dunnett-Kane2,Nicholas Williams2,Ursula McGovern3
1Royal Free London NHS Foundation Trust,2UCL Medical School,3Barnet Hospital, Royal Free London NHS Foundation Trust and University College London Hospital

BCL-3 expression is an important determinant of the DNA damage response in colorectal cancer

Year:

Session type:

Adam Chambers1,Chris Parker2,Eleanor Mortensson2,Alice Sherrard2,Kat Gash2,Ann Williams2
1,2University of Bristol

An evaluation of amendment implementation activities in an early phase clinical trials unit.

Year:

Session type:

Bindumalini Rao Baikady1,Satyanarayana Seeramreddi2,Dimitrios Magkos2,Sasha Gayle2,Mahesha Ganegoda2,Udai Banerji2,Johann de Bono2,Juanita Lopez3,Anna Minchom3,Praradchaya Lamb2
1The Institute Of Cancer Research,2The Institute Of Cancer Research and The Royal Marsden NHS Foundation Trust,3The Royal Marsden NHS Foundation Trust and The Institute Of Cancer Research

Regulation of IL-17-producing γδ T cells in breast cancer metastasis.

Year:

Session type:

Sarah C. Edwards1,Anna Kilbey2,Robert Wiesheu2,Erin R. Morris3,Liam Hayman2,Damiano Rami2,Seth B. Coffelt2
1Beatson CRUK,2Beatson CRUK. Institute of Cancer Sciences, University of Glasgow.,3Baker University, Baldwin City, Kansas

Nuclear morphometry features distinguish cell types and outcome groupings in lung cancer

Year:

Session type:

Katey Enfield1,Spencer Martin2,Erin Marshall2,Zhaolin Xu3,Martial Guillaud2,Calum MacAulay2,Wan Lam2
1British Columbia Cancer Research Centre,2BC Cancer,3Dalhousie University

Neutrophil counts and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies

Year:

Session type:

Meghan Cupp1,Margarita Cariolou1,Ioanna Tzoulaki1,Evangelou Evangelos1,Antonio Berlanga-Taylor1
1MRC-PHE Centre for Environment and Health, Department of Epidemiology & Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, St Mary's Campus, Norfolk Place, LONDON W2 1PG

Image fusion targeted prostate biopsy in 771 men at risk: a multi-centre evaluation showing low diagnostic yield of significant cancer in non-targeted biopsies

Year:

Session type:

Saiful Miah1,Feargus Hoskings-Jervis2,David Eldred-Evans2,Taimur Shah2,Mark Laniado3,Richard Hindley3,Alan Doherty3,Andrew Sinclair3,Daniel Burke3,Jeetesh Bhardwa3,Omer Karim3,Bruce Montgomery3,Simon Bott3,Neil Barber3,Raj Nigam3,Manit Arya4,Mathias Winkler1,Clare Allen4,Hashim Ahmed2
1Imperial College NHS Healthcare,2Imperial College London,3Nuada Urology London,4University College London Hospital

Phase I multicenter, open-label study to establish the maximum tolerated dose (MTD) of trifluridine/tipiracil and oxaliplatin combination in patients (pts) with metastatic colorectal cancer (mCRC)

Year:

Session type:

Mark Saunders1,Antoine Hollebecque2,Aitana Calvo3,Thierry André4,Guilem Argiles5,Andres Cervantes6,Catherine Leger7,Aude Valette7,Nadia Amellal7,Ronan Fougeray7,Josep Tabernero5
1The Christie NHS Foundation Trust, Manchester,2Drug Development Department (DITEP: Département d'Innovations Thérapeutiques et Essais Précoces), Gustave Roussy Cancer campus, Villejuif,3Gregorio Marañon University General Hospital, Madrid,4Hôpital Saint-Antoine, service d'oncologie, 184, rue du Faubourg-Saint-Antoine, Paris,5Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona,6Department of Medical Oncology, Biomedical Research Institute, Incliva, University of Valencia,7Institut de Recherches Internationales Servier, Suresnes

The CamGFR model for renal function in patients with cancer: Validation and extension for use with data from isotope mass dilution spectrometry creatinine assays

Year:

Session type:

Edward Williams1,Cameron Whitley1,Jamie Weaver2,Claire Connell1,Reed Stratton Geisler1,Daniel Giglio3,Simon Tavaré1,Duncan Jodrell1,Tobias Janowitz1
1Cancer Research UK Cambridge Institute, Cambridge,2Christie NHS Foundation Trust, Mancherster,3University of Gothenburg, Gothenburg

Embedding patient voice in cancer service improvement: A qualitative study of patients’ experience of the NHS cancer diagnostic care pathway

Year:

Session type:

Sarah Sowden1,Anna Haste1,Linda Sharp1,Mark Lambert2,Richard Thomson1
1Institute of Health and Society, Newcastle University,2Public Health England, North East Centre

Holistic needs assessments for teenagers and young adults after cancer treatment in Scotland identified a significant burden of unmet needs

Year:

Session type:

Angela Edgar1,Nicola Davison1,Simita Kumar1,Bernadine Wilkie1,Jeff White2
1NHS Lothian,2NHS Greater Glasgow and Clyde

Relapse rate and relapse patterns in patients undergoing curative resection for Pancreatic Ductal Adenocarcinoma (PDAC): Identifying high risk patients

Year:

Session type:

Akul Purohit1,Abdullah Malik2,Rahul Deshpande2,Mairead McNamara3,Thomas Satyadas2,Melissa Frizziero4,Saurabh Jamdar2,Rille Pihlak5,Aali Sheen2,Ajith Siriwardena2,Richard Hubner4,Derek O'Reilly2,Juan W Valle3,Nicola De Ligouri Carino2,Angela Lamarca4
1The Christie NHS Foundation Trust,2Hepatobiliary & Pancreatic Surgical Team, Department of Surgery, Manchester Royal Infirmary, Manchester, UK,3Medical Oncology Department, The Christie NHS Foundation Trust, Manchester, UK & Division of Cancer Sciences, University of Manchester, Manchester, UK,4Medical Oncology Department, The Christie NHS Foundation Trust, Manchester, UK,5Medical Oncology Department, The Christie NHS Foundation Trust, Manchester, UK & Division of Cancer Sciences, University of Manchester, Manchester, UK.

PET-CT surveillance post radiotherapy in advanced head and neck squamous cell cancer (HNSCC) – real life application of the PET-Neck protocol

Year:

Session type:

Suyun Zhou1,Robert Rulach1,Fraser Hendry1,David Stobo1,Mary Frances Dempsey1,Derek Grose1,Carolynn Lamb1,Allan James1,Stefano Schipani1,Mohammed Rizwannullah1,Christina Wilson1,Claire Paterson1
1GGC NHS Scotland

Using Mendelian randomization to investigate the causal effect of diet on prostate cancer

Year:

Session type:

Sarah Lewis1
1University of Bristol

Disulfiram suppresses malignant mesothelioma in vitro and in vivo by targeting hypoxia induced NF-kB pathway and cancer stem cells

Year:

Session type:

Vinodh Kannappan1,Zaixing Zhang2,Hemapriya Mahendran3,Gowtham Rajendran3,Peng Liu4,Yaohe Wang4,Peter Szlosarek4,Zhipeng Wang2,Michael Antonysamy3,Weiguang Wang2
1University of Wolverhampton,2Research Institute in Healthcare Science, Faculty of Science & Engineering, University of Wolverhampton,3PSG College of Arts and Science, Coimbatore, Tamilnadu, India,4Barts Cancer Institute, Queen Mary University of London

Aspirin use after radical cancer therapy – feasibility and toxicity data from the Add-Aspirin trial

Year:

Session type:

Nalinie Joharatnam1,Fay Cafferty1,Alistair Ring2,Howard Kynaston3,Richard Wilson4,Duncan Gilbert5,David Cameron6,Farhat Din6,Richard Hubner7,Anne Thomas8,Daniel Swinson9,Janusz Jankowski10,Sam Rowley11,Martin Scott-Brown12,Chris Price13,Alex Walther14,David Eaton15,Nicola Ainsworth16,Rachel Kerr17,Luke Hughes-Davies18,Max Parmar1,Conjeeveram Pramesh19,Sudeep Gupta19,Ruth Langley1
1MRC Clinical Trials Unit at UCL,2The Royal Marsden NHS Foundation Trust,3Cardiff and Vale University Health Board,4Queen's University Belfast,5Brighton and Sussex University Hospitals NHS Trust,6The University of Edinburgh,7The Christie NHS Foundation Trust,8University Hospitals of Leicester,9Leeds Teaching Hospitals NHS Trust,10University of Central Lancashire,11MRC CTU at UCL,12University Hospitals of Coventry and Warwickshire NHS Trust,13Worcestershire Acute Hospitals NHT Trust,14University Hospitals Bristol NHS Foundation Trust,15University Hospitals of Morecambe Bay NHS Foundation Trust,16The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust,17Oxford University Hospitals NHS Trust,18Cambridge University Hospitals NHS Foundation Trust,19Tata Memorial Centre

Molecular archaeology of cancer

Year:

Session type:

Peter Van Loo1,2

1The Francis Crick Institute, London, UK,2University of Leuven, Leuven, Belgium

NHS Cancer Strategy

Year:

Session type:

David Fitzgerald1
1NHS England

Antibody Tumour Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment

Year:

Session type:

Sean Lim1
1University of Southampton

The psychological impact of being on a monitoring pathway for early stage prostate cancer: a UK-wide mixed methods study.

Year:

Session type:

Eila Watson1,Lauren Matheson1,Sarah Wilding2,Johanna Nayoan3,Amy Downing2,Carol Rivas3,Jo Brett1,Penny Wright2,Therese Kearney4,William Cross5,Anna Gavin4,Adam Glaser2,Richard Wagland6
1Oxford Brookes University,2University of Leeds,3University College London,4Queens University Belfast,5Leeds Teaching Hospitals NHS Trust,6University of Southampton

A novel application of two-step Mendelian randomization: applying the results of small feasibility studies of interventions to infer causal effects on clinical endpoints

Year:

Session type:

Meda R. Sandu1,Rhona Beynon1,Rebecca Richmond1,Diana L. Santos Ferreira1,J Athene Lane1,Richard M. Martin1
1University of Bristol

The challenges of rare cancer: Time for change

Year:

Session type:

Richard Adams1
1Cardiff University

Modulation of Phospho Tensin Homolog (PTEN) in Cancer Cells and Lipid Peroxides in Peripheral Blood Mononuclear Cells (PBMCs) Following Exposure to Flavonoids

Year:

Session type:

William Boadi1,William Boadi1,Alekzander Garcia1,Elbert Myles1
1Tennessee State University

Trifluridine and Tipiracil (Lonsurf) for Advanced Colorectal Cancer: Response rates and Survival Data from a UK Tertiary Cancer Centre.

Year:

Session type:

Joanna Connor1
1Clatterbridge Cancer Centre

Study of diffusion weighted MRI as a predictive biomarker of response during radiotherapy (RT) for high and intermediate risk squamous cell cancer of the oropharynx: the MeRInO Study

Year:

Session type:

Claire Paterson1,Ian McCrea1,Sarah Allwood-Spiers1,Devlin Lynsey1,Lisa Hay1,Marimuthu Sankaralingam1,Philip McLoone2,Derek Grose1,Allan James1,Carolynn Lamb1,Mohammed Rizwanullah3,Christina Wilson1,Stefano Schipani1,Ioanna Nixon1,Maureen Thomson1,Mark McJury1,John Foster1,Aileen Duffton1
1NHS,2University of Glasgow,3N/A

Fine mapping the association between the Major Histocompatibility Complex and Barrett’s oesophagus/Oesophageal adenocarcinoma

Year:

Session type:

Laura Chegwidden1,Johannes Schumacher2,Rebecca Fitzgerald3,Thomas Vaughan4,Stuart MacGregor5,Puya Gharahkhani5,Janusz Jankowski6,Ian Tomlinson1,Claire Palles1
1Institute of Cancer and Genomic Sciences, University of Birmingham,2University of Bonn,3Medical Research Council (MRC) Cancer Unit, Hutchison-MRC Research Centre and University of Cambridge,4Division of Public Health Sciences, Fred Hutchinson Cancer Research Center,5QIMR Berghofer Medical Research Institute,6The Royal College of Surgeons Ireland and The University Hospitals of Morecambe Bay Hospitals NHS Trust

Defining enhanced recovery in peri-hilar cholangiocarcinoma resection.

Year:

Session type:

Leonard Quinn1,Kulbir Mann2,Abdullah Malik1,Nicholas Bird2,Robert Jones1,Declan Dunne3,Stefan Stremitzer2,Carmen Lacasia-Purroy2,Graeme Poston2,Stephen Fenwick2,Hassan Malik2
1University of Liverpool,2University Hospital Aintree,3Royal Liverpool University Hospital

Evaluation of novel isoquinolones as cytotoxic agents in hepatocellular carcinoma

Year:

Session type:

Mai Ali1,Asma Belgath1,Sally Freeman1,Katherine Finegan1,Ian Stratford1
1University of Manchester